Ameritas Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$543K Sell
1,216
-626
-34% -$292K 0.02% 549
2025
Q4
$835K Buy
1,842
+1,663
+929% +$717K 0.03% 407
2025
Q3
$70.1K Sell
179
-123
-41% -$51.4K ﹤0.01% 963
2025
Q2
$134K Buy
+302
New +$139K 0.01% 871
2024
Q3
Sell
-1,260
Closed -$591K 945
2024
Q2
$591K Buy
+1,260
New +$547K 0.02% 541
2023
Q4
Sell
-1,539
Closed -$564K 848
2023
Q3
$564K Buy
+1,539
New +$538K 0.03% 474
2023
Q2
Sell
-335
Closed -$107K 2477
2023
Q1
$107K Buy
+335
New +$100K 0.01% 979

Other funds holding VRTX

Ameritas Advisory Services's VRTX Position: Q1 2026 in Review

Ameritas Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q1 2026, selling an estimated $292K and leaving 1,216 shares worth $543K. The position accounts for 0.02% of the portfolio, ranked #549.

Ameritas Advisory Services first reported a position in VRTX in Q1 2023 and has held it in 7 quarters since. The position peaked at $835K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ameritas Advisory Services held 1,216 shares of Vertex Pharmaceuticals worth $543K as of Q1 2026.
  • Ameritas Advisory Services sold 626 Vertex Pharmaceuticals shares in Q1 2026, an estimated $292K.
  • Vertex Pharmaceuticals made up 0.02% of Ameritas Advisory Services's portfolio in Q1 2026, its #549 holding.
  • Ameritas Advisory Services first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • Ameritas Advisory Services's Vertex Pharmaceuticals position peaked at $835K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ameritas Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.